



www.isctr.org

Translational Pathways for Cardiovascular Devices Session I: Basic Knowledge for CV Devices Development

33 Multidisciplinary Lectures presented by Innovators,
Industry, Regulatory (FDA & EU), Reimbursement,
Practice Guideline, and Patients

Target Audience:

Inventors, Clinical and Basic Scientists, Interventional Cardiologists, Medical Students, Engineers, Industry, Regulators, Payers, and Investors

Welcome

- 1) *Meet the Course Directors* (**View for free online**)
 - Spencer King, MD, Emory University
 - Anthony DeMaria, MD, University of California San Diego
 - Nabil Dib, MD, ISCTR
-

Introduction

- 1) *Mission Statement*
 - Nabil Dib, MD, ISCTR (**View for free online**)
 - 2) *The Translational Pathway to Expedite Scientific Discovery to Patients*
 - Robert Califf, MD, FDA (**View for free online**)
 - 3) *Meet the Legends of Innovation Panel Discussion* (**View for free online**)
 - John Simpson, MD, Avinger
 - Alain Cribier, MD, University of Rouen
 - Gary Roubin, MD, Brookwood Baptist Health
 - Richard Schatz, MD, Scripps Clinic
 - Julio Palmaz, MD, San Francisco
 - David Reuter, MD, PhD, Seattle Children's
 - Gregg Sutton, Surmodics, Inc.
 - Bram Zuckerman, MD, FDA
 - Gregg Stone, MD, Mt. Sinai
 - Spencer King, MD, Emory University
 - Magdi Yacoub, MD, Imperial College
 - James Muller, MD, InfraRedx
 - Charles Simonton, MD, Abbott Vascular
 - Neal Farnot, PhD, Cook Group
 - Stan Rowe, NXT Biomedical
-

Session I: Basic Knowledge for CV Devices Development

Topic 1: Concept/Innovation

- 1) *Choosing an Innovative Concept*
 - Todd Brinton, MD, Edwards Lifesciences
-

Topic 2: Intellectual Property

- 2) *Intellectual Property*
- James Inskeep, Inskeep Intellectual Property Group

Topic 3: Business Plan, Product Development, and Fundraising

- 3) *Business Plan, Product Development, and Fundraising*
- Stan Rowe, NXT Biomedical

Topic 4: Product Manufacturing

- 4) *Requirements for Medical Device Manufacturing & Iteration - FDA Point of View*
- Brad Quinn, FDA
- 5) *Requirements for Medical Device Manufacturing & Iteration - Industry Point of View*
- Richard Rapoza, PhD, Abbott Vascular

Topic 5: Preclinical Evaluation/Animal Model

- 6) *Advanced Cardiac Anatomy – Application in Translational Research Tailored to Current and Future Technology*
- Renu Virmani, MD, CV Path Institute
- 7) *Introduction to the Cardiac Cath Lab*
- Morton Kern, MD, University of California Irvine & Long Beach Veterans Administration Medical Center
- 8) *Large Animal Model for Heart Failure, Valvular Disease, Coronary Artery Disease, and Device Testing*
- Daniel Burkhoff, MD, Columbia University
- 9) *Pre-Clinical Study Design & Endpoints for Device Evaluation – FDA Point of View*
- Judith Davis, DVM, MS, FDA
- 10) *Pre-Clinical Study Design & Endpoints for Device Evaluation – Investigator Point of View*
- Renu Virmani, MD, CV Path Institute

Topic 6: Early Feasibility

- 11) *Early Feasibility Studies for Device Evaluation*
- Andrew Farb, MD, FDA
- 12) *Current Challenges & Future Direction for Human Early Feasibility Study for Device Evaluation – Industry Point of View*
- David Reuter, MD, Seattle Children's Hospital

Topic 7: Biostatistics

- 13) *Basic in Statistics – Clinical Study Design for Translational Research*
- Chris Mullin, PhD, NAMSA
- 14) *Basic Statistical Concepts*
- Chris Mullin, PhD, NAMSA
- 15) *Sample Size and Power*
- Chris Mullin, PhD, NAMSA

16) *Sensitivity and Specificity*

- Chris Mullin, PhD, NAMSA

17) *Common Study Design*

- Chris Mullin, PhD, NAMSA

18) *Phases of Translational Research*

- Chris Mullin, PhD, NAMSA

19) *Statistics for Evaluation of Cardiovascular Diagnostic Devices*

- Chris Mullin, PhD, NAMSA

20) *Pre-Clinical & Clinical Trial Design & Endpoints of Fast Track to Device Approval*

- Roseann White, PhD, Duke Research Institute

21) *Advanced Statistical Methods for Translational Research*

- Chris Mullin, PhD, NAMSA

22) *Clinical Endpoints/Surrogate Endpoints*

- Roseann White, PhD, Duke Research Institute
-

Topic 8: Regulatory Approval

23) *Regulatory Requirement for Marketing Approval*

- Bram Zuckerman, MD, FDA ([View for free online](#))

24) *Regulatory Review of Cardiovascular Diagnostic Devices – FDA Perspective*

- Marco Cannella, PhD, FDA

25) *Regulatory Review of Cardiovascular Devices – European Regulatory Perspective*

- Robert Byrne, MD, Heart Center, Germany ([View for free online](#))
-

Topic 9: Reimbursement

26) *CMS Criteria for Reimbursement for Cardiovascular Innovation*

- Joseph Chin, MD, Centers for Medicare and Medicaid Services (CMS)

27) *Reimbursement for Diagnostic Devices*

- Lori Ashby, Centers for Medicare and Medicaid Services (CMS)
-

Topic 10: Practice Guideline

28) *Practice Guideline Requirement for New Technology*

- Alice Jacobs, MD, Boston University

29) *Guideline Requirements for Diagnostic Devices*

- Roxana Mehran, MD, Icahn School of Medicine, Mount Sinai
-

Topic 11: Technology Adoption

30) *Adoption of Technology*

- Ian Meredith, MD, Boston Scientific

31) *Global Heart Health, Implications for Translational Research*

- Salim Yusuf, World Federation of Cardiology
-

Topic 12: Conflict of Interest

32) *Conflict of Interest and Product Development*

- Anthony DeMaria, MD, University of Southern California San Diego

Topic 13: Patients

33) *The Patients Voice*

- Mark Mercola, PhD, Stanford Cardiovascular Institute

Panel Discussions

- 2019 Diagnostic Devices Development
- 2019 Device Development: Essential Concepts
- 2018 Requirements for CV Devices Approval
- 2017 Clinical Endpoints & Biostatistics
- 2016 Preclinical, Early Feasibility, and Safety Study for Device Development